Ozlem Küçük N, Kulak Hülya, Tokmak Emel, Tar Pnar, Ibiş Erkan, Aras Gülseren
Faculty of Medicine, Department of Nuclear Medicine, Ankara University, Turkey.
Nucl Med Commun. 2006 Apr;27(4):377-9. doi: 10.1097/01.mnm.0000202862.74917.0c.
Hürthle cell carcinoma (HCC) of the thyroid is a variant of follicular cancer which has been considered by many as a more aggressive disease than the usual well-differentiated carcinoma of the thyroid.
To investigate the clinico-pathologic characteristics, treatment and outcome of Hürthle cell carcinoma.
During a 7-year period, 13 patients (seven male, six female; mean age at diagnosis 48.4+/-13.2 years) with HCC were treated and monitored at the Ankara University. The measured diameter of the tumours varied from 1 to 6 cm in diameter with pathological examination. Three of the HCC had extra thyroid invasion, five had intrathyroid invasion, and five were encapsulated. One of the patients had a history of low-dose external radiation to the head and neck in childhood. Treatment consisted of a total thyroidectomy in 12 patients, and a near total thyroidectomy in one patient. At surgery, lymph node metastases were present in three patients and lymph node dissection were performed in these patients. Distant metastases were detected in only one patient (lung metastasis).
All patients had radioiodine ablation therapy for residual thyroid tissue. Twelve of the 13 patients were ablated with a single dose of 131 I (3.7-5.5 GBq). A second dose of radioiodine therapy was required in only one patient who had lung metastases and this patient is still being followed up. After a median follow-up period of 85 months, there was no recorded mortality due to the disease and 12/13 of the patients were categorized as disease free (criteria for ablation were a negative I whole-body scan and very low serum thyroglobulin levels).
We did not find higher incidences of local recurrences, distant metastases or mortality rates compared to well differentiated thyroid carcinomas. HCC of the thyroid and well differentiated thyroid carcinomas have similar biological behaviour. Their treatment should be similar, including total or near-total thyroidectomy plus modified cervical node dissection when there is lymph node involvement. Radioactive iodine therapy and suppressive laevothyroxin therapy should follow.
甲状腺嗜酸性细胞癌(HCC)是滤泡癌的一种变体,许多人认为它比常见的甲状腺高分化癌更具侵袭性。
研究甲状腺嗜酸性细胞癌的临床病理特征、治疗方法及预后。
在7年期间,安卡拉大学对13例甲状腺嗜酸性细胞癌患者(7例男性,6例女性;诊断时平均年龄48.4±13.2岁)进行了治疗和监测。经病理检查,肿瘤直径测量值在1至6厘米之间。其中3例甲状腺嗜酸性细胞癌有甲状腺外侵犯,5例有甲状腺内侵犯,5例有包膜。1例患者童年时有头颈部低剂量外照射史。12例患者接受了全甲状腺切除术,1例患者接受了近全甲状腺切除术。手术时,3例患者出现淋巴结转移,并对这些患者进行了淋巴结清扫。仅1例患者检测到远处转移(肺转移)。
所有患者均接受了放射性碘消融治疗残留甲状腺组织。13例患者中有12例接受了单次131I剂量(3.7 - 5.5GBq)的消融。仅1例有肺转移的患者需要第二次放射性碘治疗,该患者仍在随访中。中位随访期85个月后,无因该病记录的死亡病例,13例患者中有12例被归类为无病(消融标准为全身碘扫描阴性和血清甲状腺球蛋白水平极低)。
与高分化甲状腺癌相比,我们未发现局部复发、远处转移或死亡率有更高的发生率。甲状腺嗜酸性细胞癌和高分化甲状腺癌具有相似的生物学行为。它们的治疗方法应相似,包括全甲状腺或近全甲状腺切除术,当有淋巴结受累时加改良颈部淋巴结清扫术。随后应进行放射性碘治疗和左甲状腺素抑制治疗。